| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Iran | 151 | 2024 | 711 | 16.410 |
Why?
|
| Quality-Adjusted Life Years | 61 | 2024 | 1708 | 5.100 |
Why?
|
| Accidents, Traffic | 8 | 2023 | 812 | 3.660 |
Why?
|
| Sodium Chloride, Dietary | 6 | 2021 | 288 | 3.340 |
Why?
|
| Automobile Driving | 6 | 2023 | 434 | 3.200 |
Why?
|
| Cost of Illness | 21 | 2023 | 1912 | 2.750 |
Why?
|
| Prevalence | 71 | 2024 | 15508 | 2.640 |
Why?
|
| Disabled Persons | 10 | 2024 | 1217 | 2.370 |
Why?
|
| Child Mortality | 7 | 2023 | 201 | 2.310 |
Why?
|
| Life Expectancy | 15 | 2024 | 1243 | 2.300 |
Why?
|
| Hypertension | 21 | 2024 | 8498 | 2.150 |
Why?
|
| Incidence | 53 | 2024 | 21157 | 2.020 |
Why?
|
| Diabetes Mellitus | 23 | 2024 | 5839 | 1.990 |
Why?
|
| Overweight | 9 | 2024 | 2400 | 1.900 |
Why?
|
| Health Surveys | 18 | 2022 | 4010 | 1.810 |
Why?
|
| Quality of Health Care | 20 | 2024 | 4343 | 1.810 |
Why?
|
| Tobacco Smoke Pollution | 4 | 2023 | 810 | 1.680 |
Why?
|
| Infant Mortality | 5 | 2023 | 747 | 1.630 |
Why?
|
| Wounds and Injuries | 13 | 2021 | 2427 | 1.540 |
Why?
|
| Hypercholesterolemia | 7 | 2023 | 1154 | 1.500 |
Why?
|
| Middle East | 14 | 2024 | 222 | 1.500 |
Why?
|
| Male | 166 | 2024 | 354908 | 1.450 |
Why?
|
| Risk Factors | 78 | 2024 | 73425 | 1.450 |
Why?
|
| Endocarditis | 3 | 2024 | 347 | 1.380 |
Why?
|
| Age Distribution | 23 | 2024 | 2884 | 1.380 |
Why?
|
| Humans | 263 | 2024 | 752411 | 1.370 |
Why?
|
| Myocardial Ischemia | 5 | 2024 | 2155 | 1.340 |
Why?
|
| Sex Distribution | 20 | 2024 | 2290 | 1.330 |
Why?
|
| Female | 168 | 2024 | 386085 | 1.330 |
Why?
|
| Africa, Northern | 10 | 2024 | 84 | 1.320 |
Why?
|
| Epidemiologic Research Design | 15 | 2014 | 365 | 1.310 |
Why?
|
| Dental Caries | 2 | 2023 | 421 | 1.310 |
Why?
|
| Obesity | 16 | 2024 | 12806 | 1.250 |
Why?
|
| Stomach Neoplasms | 7 | 2023 | 1397 | 1.220 |
Why?
|
| Cardiovascular Diseases | 26 | 2024 | 15622 | 1.190 |
Why?
|
| Developing Countries | 21 | 2024 | 2819 | 1.180 |
Why?
|
| Prediabetic State | 2 | 2023 | 529 | 1.150 |
Why?
|
| Particulate Matter | 7 | 2024 | 2528 | 1.140 |
Why?
|
| Air Pollution, Indoor | 2 | 2024 | 875 | 1.120 |
Why?
|
| Feeding Behavior | 7 | 2023 | 3174 | 1.110 |
Why?
|
| Hepatitis C | 3 | 2022 | 1573 | 1.110 |
Why?
|
| Air Pollutants | 5 | 2024 | 2813 | 1.070 |
Why?
|
| Adult | 110 | 2024 | 216927 | 1.060 |
Why?
|
| Mortality | 16 | 2021 | 2882 | 1.060 |
Why?
|
| Cross-Sectional Studies | 41 | 2024 | 25539 | 1.040 |
Why?
|
| Exercise | 5 | 2023 | 5746 | 1.010 |
Why?
|
| Bayes Theorem | 19 | 2024 | 2280 | 1.010 |
Why?
|
| Antihypertensive Agents | 7 | 2023 | 2036 | 1.000 |
Why?
|
| Epidemiology | 4 | 2017 | 275 | 0.980 |
Why?
|
| Unionidae | 1 | 2024 | 1 | 0.960 |
Why?
|
| Registries | 15 | 2021 | 8367 | 0.960 |
Why?
|
| Physicians, Family | 2 | 2017 | 351 | 0.950 |
Why?
|
| Socioeconomic Factors | 21 | 2023 | 7747 | 0.940 |
Why?
|
| Rural Population | 8 | 2023 | 2239 | 0.920 |
Why?
|
| Hepatitis B | 2 | 2020 | 697 | 0.910 |
Why?
|
| Environmental Exposure | 7 | 2024 | 4341 | 0.900 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2022 | 905 | 0.880 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 5 | 2022 | 3146 | 0.880 |
Why?
|
| Automobiles | 2 | 2021 | 112 | 0.880 |
Why?
|
| Aged | 80 | 2024 | 166585 | 0.860 |
Why?
|
| Tooth, Deciduous | 1 | 2022 | 75 | 0.840 |
Why?
|
| Young Adult | 49 | 2024 | 57632 | 0.820 |
Why?
|
| Head Protective Devices | 2 | 2021 | 110 | 0.800 |
Why?
|
| Middle Aged | 88 | 2024 | 217039 | 0.790 |
Why?
|
| Tooth Loss | 1 | 2023 | 199 | 0.770 |
Why?
|
| Mercury | 1 | 2024 | 290 | 0.760 |
Why?
|
| Income | 9 | 2022 | 1864 | 0.760 |
Why?
|
| Cities | 3 | 2024 | 528 | 0.760 |
Why?
|
| Breast Neoplasms, Male | 1 | 2023 | 220 | 0.760 |
Why?
|
| Polypharmacy | 1 | 2024 | 305 | 0.750 |
Why?
|
| Rural Health Services | 2 | 2017 | 379 | 0.740 |
Why?
|
| Peptic Ulcer | 1 | 2022 | 219 | 0.740 |
Why?
|
| Cause of Death | 13 | 2021 | 3685 | 0.740 |
Why?
|
| Blood Pressure | 13 | 2023 | 8465 | 0.720 |
Why?
|
| Maternal Mortality | 2 | 2021 | 285 | 0.710 |
Why?
|
| Hypertriglyceridemia | 1 | 2023 | 312 | 0.700 |
Why?
|
| Economics | 1 | 2020 | 141 | 0.690 |
Why?
|
| Seat Belts | 1 | 2019 | 58 | 0.670 |
Why?
|
| Metals, Heavy | 1 | 2021 | 143 | 0.670 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2023 | 409 | 0.660 |
Why?
|
| Models, Statistical | 13 | 2021 | 5045 | 0.660 |
Why?
|
| Respiration Disorders | 1 | 2022 | 369 | 0.660 |
Why?
|
| Body Mass Index | 16 | 2022 | 12796 | 0.650 |
Why?
|
| Adolescent | 45 | 2024 | 86766 | 0.630 |
Why?
|
| Health Policy | 4 | 2023 | 2656 | 0.630 |
Why?
|
| Infant, Newborn | 27 | 2024 | 25919 | 0.620 |
Why?
|
| Pesticides | 1 | 2021 | 281 | 0.620 |
Why?
|
| Asthma | 6 | 2022 | 6145 | 0.620 |
Why?
|
| Helicobacter Infections | 2 | 2021 | 380 | 0.610 |
Why?
|
| Health Status | 7 | 2024 | 4050 | 0.610 |
Why?
|
| Insulin Infusion Systems | 1 | 2019 | 212 | 0.600 |
Why?
|
| Bibliometrics | 1 | 2021 | 343 | 0.600 |
Why?
|
| Goals | 3 | 2019 | 701 | 0.590 |
Why?
|
| Helicobacter pylori | 1 | 2021 | 373 | 0.590 |
Why?
|
| Vital Statistics | 1 | 2017 | 30 | 0.570 |
Why?
|
| Transportation | 1 | 2018 | 215 | 0.560 |
Why?
|
| Stroke | 7 | 2022 | 9879 | 0.550 |
Why?
|
| Public Health | 6 | 2021 | 2646 | 0.540 |
Why?
|
| Liver Neoplasms | 3 | 2022 | 4271 | 0.520 |
Why?
|
| Population Surveillance | 4 | 2020 | 2598 | 0.500 |
Why?
|
| Data Collection | 3 | 2022 | 3301 | 0.500 |
Why?
|
| Environmental Monitoring | 4 | 2024 | 1421 | 0.490 |
Why?
|
| Genital Neoplasms, Female | 1 | 2020 | 525 | 0.490 |
Why?
|
| Government Programs | 1 | 2017 | 279 | 0.490 |
Why?
|
| Commerce | 1 | 2020 | 596 | 0.480 |
Why?
|
| Urologic Neoplasms | 1 | 2018 | 321 | 0.480 |
Why?
|
| Midwifery | 1 | 2016 | 123 | 0.470 |
Why?
|
| Child, Preschool | 27 | 2024 | 41660 | 0.470 |
Why?
|
| Infant | 25 | 2024 | 35675 | 0.470 |
Why?
|
| Guidelines as Topic | 2 | 2021 | 1387 | 0.470 |
Why?
|
| Heart Valve Diseases | 1 | 2022 | 1047 | 0.470 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2024 | 1995 | 0.470 |
Why?
|
| Life Style | 5 | 2024 | 3859 | 0.460 |
Why?
|
| Leukemia | 1 | 2022 | 1500 | 0.460 |
Why?
|
| Disability Evaluation | 3 | 2019 | 1800 | 0.460 |
Why?
|
| Environmental Illness | 1 | 2014 | 34 | 0.460 |
Why?
|
| Safety | 1 | 2018 | 1146 | 0.460 |
Why?
|
| Air Pollution | 4 | 2023 | 2296 | 0.450 |
Why?
|
| Program Development | 1 | 2020 | 1287 | 0.450 |
Why?
|
| Social Class | 6 | 2022 | 1992 | 0.450 |
Why?
|
| Feedback | 3 | 2023 | 783 | 0.450 |
Why?
|
| Earthquakes | 1 | 2016 | 183 | 0.450 |
Why?
|
| DMF Index | 2 | 2023 | 86 | 0.440 |
Why?
|
| Motivation | 1 | 2023 | 1976 | 0.440 |
Why?
|
| Sodium | 1 | 2018 | 1592 | 0.440 |
Why?
|
| Diabetes, Gestational | 4 | 2023 | 1227 | 0.430 |
Why?
|
| Neoplasms | 8 | 2022 | 21806 | 0.430 |
Why?
|
| Aged, 80 and over | 31 | 2024 | 58299 | 0.430 |
Why?
|
| Nutritional Status | 2 | 2021 | 1596 | 0.430 |
Why?
|
| Alcohol Drinking | 3 | 2024 | 3990 | 0.420 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2018 | 3935 | 0.420 |
Why?
|
| Research Design | 5 | 2018 | 6113 | 0.420 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2024 | 2242 | 0.420 |
Why?
|
| National Health Programs | 1 | 2016 | 442 | 0.420 |
Why?
|
| Liver Cirrhosis | 2 | 2022 | 1892 | 0.410 |
Why?
|
| Health Status Disparities | 5 | 2021 | 1775 | 0.410 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2022 | 2252 | 0.410 |
Why?
|
| Metabolome | 2 | 2019 | 967 | 0.410 |
Why?
|
| Multilevel Analysis | 5 | 2014 | 144 | 0.410 |
Why?
|
| Child | 31 | 2024 | 79004 | 0.400 |
Why?
|
| Diabetes Mellitus, Type 2 | 5 | 2024 | 12151 | 0.400 |
Why?
|
| Awareness | 1 | 2016 | 616 | 0.400 |
Why?
|
| Regression Analysis | 9 | 2021 | 6358 | 0.380 |
Why?
|
| World Health Organization | 4 | 2023 | 1294 | 0.380 |
Why?
|
| Medical Records | 2 | 2014 | 1403 | 0.380 |
Why?
|
| Oral Health | 3 | 2023 | 477 | 0.370 |
Why?
|
| Arsenic | 2 | 2024 | 343 | 0.370 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2023 | 3374 | 0.370 |
Why?
|
| History, 20th Century | 4 | 2020 | 2759 | 0.370 |
Why?
|
| History, 21st Century | 4 | 2020 | 1559 | 0.360 |
Why?
|
| Multiple Sclerosis | 2 | 2023 | 3141 | 0.350 |
Why?
|
| Primary Health Care | 5 | 2021 | 4621 | 0.350 |
Why?
|
| Disasters | 1 | 2016 | 511 | 0.350 |
Why?
|
| Policy Making | 1 | 2014 | 539 | 0.350 |
Why?
|
| Cesarean Section | 3 | 2023 | 1374 | 0.350 |
Why?
|
| Vitamins | 1 | 2018 | 1632 | 0.340 |
Why?
|
| Metals | 2 | 2024 | 726 | 0.340 |
Why?
|
| Cholesterol | 6 | 2022 | 2904 | 0.330 |
Why?
|
| Fraud | 2 | 2020 | 65 | 0.320 |
Why?
|
| Mental Disorders | 2 | 2022 | 6696 | 0.320 |
Why?
|
| Photography | 2 | 2022 | 531 | 0.320 |
Why?
|
| Lead | 2 | 2024 | 859 | 0.310 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2021 | 2269 | 0.310 |
Why?
|
| Sarcopenia | 2 | 2024 | 366 | 0.310 |
Why?
|
| Smoking | 6 | 2021 | 9028 | 0.310 |
Why?
|
| Amino Acids | 4 | 2023 | 1713 | 0.310 |
Why?
|
| Smoking Cessation | 1 | 2020 | 2077 | 0.310 |
Why?
|
| Lung Neoplasms | 3 | 2022 | 13167 | 0.310 |
Why?
|
| Health Services Accessibility | 4 | 2022 | 5282 | 0.300 |
Why?
|
| Blood Glucose | 9 | 2023 | 6331 | 0.300 |
Why?
|
| Kidney | 1 | 2023 | 6984 | 0.290 |
Why?
|
| Vision Disorders | 1 | 2014 | 1072 | 0.290 |
Why?
|
| Lipids | 1 | 2018 | 3329 | 0.290 |
Why?
|
| Kidney Neoplasms | 1 | 2024 | 4275 | 0.280 |
Why?
|
| Ovarian Neoplasms | 1 | 2024 | 4808 | 0.280 |
Why?
|
| Databases, Factual | 10 | 2021 | 7897 | 0.280 |
Why?
|
| Sex Factors | 12 | 2021 | 10457 | 0.280 |
Why?
|
| Time Factors | 15 | 2021 | 39846 | 0.280 |
Why?
|
| Risk Assessment | 14 | 2023 | 23788 | 0.270 |
Why?
|
| Aspirin | 4 | 2024 | 3341 | 0.270 |
Why?
|
| Markov Chains | 5 | 2020 | 968 | 0.270 |
Why?
|
| Dyslipidemias | 1 | 2014 | 890 | 0.270 |
Why?
|
| Bipolar Disorder | 1 | 2023 | 5069 | 0.260 |
Why?
|
| Health Services Needs and Demand | 1 | 2014 | 1391 | 0.260 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2010 | 449 | 0.260 |
Why?
|
| Age Factors | 13 | 2021 | 18298 | 0.250 |
Why?
|
| Demography | 3 | 2021 | 1638 | 0.250 |
Why?
|
| Computer Simulation | 1 | 2018 | 6166 | 0.250 |
Why?
|
| Hospitals | 2 | 2021 | 3915 | 0.250 |
Why?
|
| Insulin | 1 | 2019 | 6569 | 0.240 |
Why?
|
| Pancreatic Neoplasms | 2 | 2021 | 5288 | 0.240 |
Why?
|
| Pyrenes | 1 | 2024 | 47 | 0.240 |
Why?
|
| Vitamin D | 1 | 2018 | 3273 | 0.240 |
Why?
|
| Health Promotion | 1 | 2016 | 2200 | 0.240 |
Why?
|
| Carnitine | 3 | 2022 | 252 | 0.230 |
Why?
|
| Projection | 1 | 2023 | 18 | 0.230 |
Why?
|
| Prescriptions | 2 | 2024 | 385 | 0.230 |
Why?
|
| Healthcare Disparities | 3 | 2020 | 3302 | 0.230 |
Why?
|
| Dentition, Permanent | 1 | 2023 | 22 | 0.230 |
Why?
|
| Geography | 3 | 2021 | 659 | 0.220 |
Why?
|
| Aluminum | 1 | 2024 | 152 | 0.220 |
Why?
|
| Nickel | 1 | 2024 | 127 | 0.220 |
Why?
|
| Chromium | 1 | 2024 | 132 | 0.220 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2024 | 352 | 0.220 |
Why?
|
| Tunisia | 1 | 2022 | 36 | 0.220 |
Why?
|
| Early Detection of Cancer | 3 | 2022 | 3166 | 0.220 |
Why?
|
| Osteoporosis | 2 | 2022 | 1589 | 0.210 |
Why?
|
| Alkaloids | 1 | 2024 | 193 | 0.210 |
Why?
|
| Cadmium | 1 | 2024 | 215 | 0.210 |
Why?
|
| Toothbrushing | 1 | 2022 | 45 | 0.210 |
Why?
|
| Lebanon | 1 | 2023 | 241 | 0.210 |
Why?
|
| Chronic Disease | 2 | 2015 | 9162 | 0.210 |
Why?
|
| Risk Reduction Behavior | 2 | 2019 | 1096 | 0.210 |
Why?
|
| Fetal Macrosomia | 4 | 2023 | 127 | 0.200 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 6792 | 0.200 |
Why?
|
| Clinical Protocols | 4 | 2014 | 1436 | 0.200 |
Why?
|
| Data Mining | 2 | 2018 | 544 | 0.200 |
Why?
|
| Pandemics | 4 | 2022 | 8511 | 0.200 |
Why?
|
| Disease Outbreaks | 2 | 2014 | 1739 | 0.190 |
Why?
|
| Tobacco, Smokeless | 1 | 2022 | 130 | 0.190 |
Why?
|
| PubMed | 1 | 2021 | 126 | 0.190 |
Why?
|
| Pregnancy Complications | 2 | 2017 | 2921 | 0.190 |
Why?
|
| Insulin Resistance | 3 | 2022 | 3913 | 0.190 |
Why?
|
| Premature Birth | 2 | 2023 | 1742 | 0.190 |
Why?
|
| Rheumatic Heart Disease | 1 | 2022 | 165 | 0.190 |
Why?
|
| Skin Neoplasms | 1 | 2020 | 5726 | 0.190 |
Why?
|
| Sampling Studies | 1 | 2022 | 616 | 0.180 |
Why?
|
| Pregnancy in Diabetics | 1 | 2022 | 191 | 0.180 |
Why?
|
| Metabolomics | 5 | 2023 | 1602 | 0.180 |
Why?
|
| Gallbladder | 1 | 2021 | 306 | 0.180 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2023 | 266 | 0.180 |
Why?
|
| Child, Hospitalized | 1 | 2021 | 180 | 0.180 |
Why?
|
| Lip | 1 | 2021 | 191 | 0.170 |
Why?
|
| Health Transition | 2 | 2019 | 34 | 0.170 |
Why?
|
| Ozone | 1 | 2023 | 467 | 0.170 |
Why?
|
| Poverty Areas | 1 | 2021 | 263 | 0.170 |
Why?
|
| Housing | 1 | 2024 | 656 | 0.170 |
Why?
|
| Urban Population | 3 | 2022 | 2005 | 0.170 |
Why?
|
| History of Medicine | 1 | 2019 | 42 | 0.160 |
Why?
|
| Sphingomyelins | 1 | 2019 | 103 | 0.160 |
Why?
|
| Systole | 1 | 2021 | 948 | 0.160 |
Why?
|
| Mediterranean Region | 4 | 2019 | 47 | 0.160 |
Why?
|
| Influenza, Human | 1 | 2010 | 1528 | 0.160 |
Why?
|
| Telecommunications | 1 | 2018 | 80 | 0.160 |
Why?
|
| Thyroid Neoplasms | 2 | 2022 | 2309 | 0.150 |
Why?
|
| Mitral Valve Prolapse | 1 | 2020 | 215 | 0.150 |
Why?
|
| Diet | 3 | 2023 | 7949 | 0.150 |
Why?
|
| Insurance, Health | 3 | 2020 | 2490 | 0.150 |
Why?
|
| Hypothyroidism | 1 | 2023 | 663 | 0.150 |
Why?
|
| Fruit | 1 | 2023 | 1160 | 0.150 |
Why?
|
| Taxes | 1 | 2020 | 219 | 0.150 |
Why?
|
| Breast Neoplasms | 2 | 2022 | 20840 | 0.150 |
Why?
|
| Australia | 1 | 2021 | 1277 | 0.150 |
Why?
|
| Monte Carlo Method | 4 | 2020 | 1267 | 0.150 |
Why?
|
| Policy | 1 | 2021 | 505 | 0.150 |
Why?
|
| Death Certificates | 1 | 2018 | 167 | 0.150 |
Why?
|
| Substance-Related Disorders | 1 | 2014 | 4320 | 0.150 |
Why?
|
| Phosphatidylcholines | 1 | 2019 | 406 | 0.150 |
Why?
|
| Japan | 1 | 2021 | 1333 | 0.140 |
Why?
|
| Peer Group | 1 | 2022 | 656 | 0.140 |
Why?
|
| Magnetite Nanoparticles | 1 | 2019 | 316 | 0.140 |
Why?
|
| Anthropometry | 1 | 2022 | 1342 | 0.140 |
Why?
|
| State Health Plans | 1 | 2019 | 220 | 0.140 |
Why?
|
| Health Services | 1 | 2022 | 751 | 0.140 |
Why?
|
| Nitrogen Dioxide | 1 | 2019 | 496 | 0.140 |
Why?
|
| Pregnancy | 10 | 2023 | 29441 | 0.140 |
Why?
|
| Secondary Prevention | 1 | 2023 | 1546 | 0.140 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2022 | 588 | 0.140 |
Why?
|
| Headache Disorders | 1 | 2019 | 139 | 0.140 |
Why?
|
| Reference Values | 1 | 2024 | 4898 | 0.140 |
Why?
|
| Lysophospholipids | 1 | 2019 | 339 | 0.140 |
Why?
|
| Primary Prevention | 1 | 2024 | 1184 | 0.140 |
Why?
|
| Visually Impaired Persons | 1 | 2017 | 75 | 0.140 |
Why?
|
| Urinalysis | 1 | 2018 | 367 | 0.140 |
Why?
|
| Reference Standards | 1 | 2020 | 1004 | 0.130 |
Why?
|
| Blood Pressure Determination | 1 | 2020 | 633 | 0.130 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2022 | 3303 | 0.130 |
Why?
|
| Social Problems | 1 | 2016 | 109 | 0.130 |
Why?
|
| Forecasting | 2 | 2022 | 2916 | 0.130 |
Why?
|
| Censuses | 1 | 2017 | 200 | 0.130 |
Why?
|
| Survival Rate | 3 | 2019 | 12745 | 0.130 |
Why?
|
| Gastrointestinal Diseases | 2 | 2014 | 1176 | 0.130 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2020 | 583 | 0.130 |
Why?
|
| Homicide | 1 | 2018 | 294 | 0.130 |
Why?
|
| Central Nervous System | 1 | 2022 | 1330 | 0.130 |
Why?
|
| Achievement | 1 | 2017 | 289 | 0.130 |
Why?
|
| Developed Countries | 3 | 2023 | 434 | 0.130 |
Why?
|
| Neck Pain | 1 | 2017 | 183 | 0.130 |
Why?
|
| Vision, Low | 1 | 2017 | 160 | 0.130 |
Why?
|
| Bronchitis, Chronic | 1 | 2016 | 82 | 0.130 |
Why?
|
| Tandem Mass Spectrometry | 4 | 2022 | 1179 | 0.130 |
Why?
|
| Phenols | 1 | 2019 | 513 | 0.120 |
Why?
|
| Self Report | 3 | 2023 | 3647 | 0.120 |
Why?
|
| Task Performance and Analysis | 1 | 2018 | 754 | 0.120 |
Why?
|
| Diabetes Complications | 1 | 2021 | 1341 | 0.120 |
Why?
|
| Fast Foods | 1 | 2016 | 208 | 0.120 |
Why?
|
| Family Practice | 1 | 2017 | 507 | 0.120 |
Why?
|
| Publishing | 1 | 2021 | 834 | 0.120 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 2197 | 0.110 |
Why?
|
| Cholesterol, LDL | 1 | 2023 | 2407 | 0.110 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2020 | 950 | 0.110 |
Why?
|
| Opium | 1 | 2013 | 27 | 0.110 |
Why?
|
| Food Labeling | 1 | 2016 | 181 | 0.110 |
Why?
|
| Stress, Mechanical | 1 | 2019 | 1661 | 0.110 |
Why?
|
| Pre-Eclampsia | 1 | 2023 | 1204 | 0.110 |
Why?
|
| Nutrition Surveys | 1 | 2021 | 1697 | 0.110 |
Why?
|
| Dental Health Services | 1 | 2013 | 49 | 0.110 |
Why?
|
| Dementia | 3 | 2019 | 2585 | 0.110 |
Why?
|
| Normal Distribution | 1 | 2014 | 271 | 0.110 |
Why?
|
| Chromatography, Liquid | 3 | 2022 | 978 | 0.110 |
Why?
|
| China | 1 | 2019 | 2337 | 0.110 |
Why?
|
| Blindness | 1 | 2017 | 581 | 0.110 |
Why?
|
| Prisons | 1 | 2014 | 162 | 0.110 |
Why?
|
| Decision Trees | 1 | 2014 | 504 | 0.110 |
Why?
|
| Diarrhea | 2 | 2016 | 1336 | 0.110 |
Why?
|
| Testicular Neoplasms | 1 | 2019 | 795 | 0.110 |
Why?
|
| Principal Component Analysis | 1 | 2016 | 935 | 0.110 |
Why?
|
| Diuretics | 1 | 2016 | 611 | 0.100 |
Why?
|
| Bone Density | 2 | 2022 | 3498 | 0.100 |
Why?
|
| Review Literature as Topic | 1 | 2014 | 333 | 0.100 |
Why?
|
| Calcium Channel Blockers | 1 | 2016 | 690 | 0.100 |
Why?
|
| alpha-Synuclein | 1 | 2019 | 745 | 0.100 |
Why?
|
| HIV Infections | 5 | 2022 | 16984 | 0.100 |
Why?
|
| Urbanization | 1 | 2013 | 100 | 0.100 |
Why?
|
| Wounds, Gunshot | 1 | 2018 | 578 | 0.100 |
Why?
|
| Pregnancy Outcome | 4 | 2023 | 2864 | 0.100 |
Why?
|
| Benzhydryl Compounds | 1 | 2019 | 933 | 0.100 |
Why?
|
| Ascorbic Acid | 1 | 2015 | 653 | 0.100 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2014 | 345 | 0.100 |
Why?
|
| Health Behavior | 2 | 2021 | 2615 | 0.100 |
Why?
|
| Survival Analysis | 3 | 2020 | 10172 | 0.100 |
Why?
|
| Respiratory Tract Infections | 1 | 2019 | 995 | 0.100 |
Why?
|
| Mouth Diseases | 1 | 2014 | 235 | 0.100 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2016 | 1515 | 0.100 |
Why?
|
| International Classification of Diseases | 1 | 2017 | 875 | 0.100 |
Why?
|
| Prescription Drugs | 1 | 2018 | 624 | 0.100 |
Why?
|
| Narcotics | 1 | 2013 | 335 | 0.090 |
Why?
|
| Calcinosis | 1 | 2020 | 1478 | 0.090 |
Why?
|
| Vitamin E | 1 | 2015 | 872 | 0.090 |
Why?
|
| Logistic Models | 3 | 2022 | 13277 | 0.090 |
Why?
|
| Health Care Reform | 1 | 2020 | 1244 | 0.090 |
Why?
|
| Firearms | 1 | 2018 | 618 | 0.090 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 1660 | 0.090 |
Why?
|
| Case-Control Studies | 4 | 2022 | 21851 | 0.090 |
Why?
|
| Equipment Design | 1 | 2018 | 3511 | 0.090 |
Why?
|
| Delivery of Health Care | 4 | 2022 | 5279 | 0.090 |
Why?
|
| Prognosis | 3 | 2021 | 29337 | 0.090 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2022 | 3117 | 0.090 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2020 | 1411 | 0.090 |
Why?
|
| Research | 1 | 2018 | 1962 | 0.090 |
Why?
|
| Neurodegenerative Diseases | 1 | 2019 | 1065 | 0.090 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2016 | 1247 | 0.090 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2014 | 530 | 0.090 |
Why?
|
| Respiratory Tract Diseases | 1 | 2015 | 745 | 0.090 |
Why?
|
| Gout | 1 | 2017 | 595 | 0.090 |
Why?
|
| Aortic Valve | 1 | 2020 | 1992 | 0.090 |
Why?
|
| Glucose Tolerance Test | 2 | 2023 | 1169 | 0.090 |
Why?
|
| Education, Medical | 1 | 2021 | 1713 | 0.090 |
Why?
|
| Psychiatry | 1 | 2022 | 1691 | 0.090 |
Why?
|
| Meta-Analysis as Topic | 1 | 2014 | 1365 | 0.090 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2016 | 1002 | 0.080 |
Why?
|
| Aging | 3 | 2024 | 8582 | 0.080 |
Why?
|
| DNA Damage | 1 | 2019 | 2407 | 0.080 |
Why?
|
| Osteoarthritis | 1 | 2017 | 1052 | 0.080 |
Why?
|
| Comorbidity | 2 | 2023 | 10475 | 0.080 |
Why?
|
| Metabolic Diseases | 1 | 2015 | 685 | 0.080 |
Why?
|
| Program Evaluation | 1 | 2017 | 2464 | 0.080 |
Why?
|
| Low Back Pain | 1 | 2017 | 966 | 0.080 |
Why?
|
| Organizational Objectives | 3 | 2014 | 428 | 0.080 |
Why?
|
| Preventive Health Services | 1 | 2013 | 569 | 0.080 |
Why?
|
| Suicide | 1 | 2018 | 1505 | 0.070 |
Why?
|
| Retrospective Studies | 6 | 2023 | 79133 | 0.070 |
Why?
|
| Antioxidants | 1 | 2015 | 1651 | 0.070 |
Why?
|
| Health Resources | 1 | 2013 | 920 | 0.070 |
Why?
|
| Aortic Valve Stenosis | 1 | 2020 | 2067 | 0.070 |
Why?
|
| Occupational Diseases | 1 | 2015 | 1481 | 0.070 |
Why?
|
| International Cooperation | 1 | 2013 | 1421 | 0.070 |
Why?
|
| Communicable Diseases | 1 | 2015 | 872 | 0.070 |
Why?
|
| Nutrition Policy | 1 | 2011 | 473 | 0.070 |
Why?
|
| Universities | 2 | 2022 | 950 | 0.070 |
Why?
|
| Vaccination | 1 | 2019 | 3322 | 0.070 |
Why?
|
| Precancerous Conditions | 1 | 2013 | 969 | 0.070 |
Why?
|
| Fasting | 3 | 2023 | 1590 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2021 | 3379 | 0.070 |
Why?
|
| Poverty | 3 | 2022 | 2640 | 0.060 |
Why?
|
| Liver Diseases | 1 | 2014 | 1276 | 0.060 |
Why?
|
| DNA | 1 | 2019 | 7215 | 0.060 |
Why?
|
| Morbidity | 2 | 2020 | 1757 | 0.060 |
Why?
|
| Malaria | 1 | 2014 | 1207 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2019 | 64250 | 0.060 |
Why?
|
| Depressive Disorder, Major | 1 | 2022 | 4691 | 0.060 |
Why?
|
| Risk | 2 | 2013 | 9613 | 0.060 |
Why?
|
| Double-Blind Method | 1 | 2018 | 12328 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 19901 | 0.060 |
Why?
|
| Colitis, Ulcerative | 1 | 2016 | 1911 | 0.060 |
Why?
|
| Phenotype | 2 | 2018 | 16443 | 0.060 |
Why?
|
| Crohn Disease | 1 | 2016 | 2255 | 0.050 |
Why?
|
| Dietary Supplements | 1 | 2015 | 3370 | 0.050 |
Why?
|
| Models, Theoretical | 3 | 2021 | 3546 | 0.050 |
Why?
|
| Fibrinolytic Agents | 1 | 2012 | 2167 | 0.050 |
Why?
|
| Kidney Failure, Chronic | 1 | 2014 | 2422 | 0.050 |
Why?
|
| Inpatients | 1 | 2014 | 2562 | 0.050 |
Why?
|
| Atrial Fibrillation | 1 | 2021 | 5148 | 0.050 |
Why?
|
| Physicians | 1 | 2020 | 4551 | 0.050 |
Why?
|
| Algorithms | 2 | 2020 | 13897 | 0.050 |
Why?
|
| Neglected Diseases | 1 | 2022 | 65 | 0.050 |
Why?
|
| Africa | 2 | 2016 | 697 | 0.050 |
Why?
|
| Enalapril | 1 | 2023 | 310 | 0.050 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2023 | 217 | 0.050 |
Why?
|
| Tuberculosis | 1 | 2014 | 1988 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2022 | 389 | 0.050 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2017 | 3752 | 0.050 |
Why?
|
| Small-Area Analysis | 1 | 2021 | 55 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 15680 | 0.050 |
Why?
|
| Educational Status | 2 | 2020 | 2499 | 0.050 |
Why?
|
| Space-Time Clustering | 1 | 2020 | 46 | 0.050 |
Why?
|
| Amyloid beta-Peptides | 1 | 2014 | 3807 | 0.040 |
Why?
|
| NAD | 1 | 2024 | 594 | 0.040 |
Why?
|
| Africa South of the Sahara | 1 | 2022 | 728 | 0.040 |
Why?
|
| Persia | 1 | 2019 | 7 | 0.040 |
Why?
|
| England | 1 | 2021 | 516 | 0.040 |
Why?
|
| Glycine | 1 | 2023 | 658 | 0.040 |
Why?
|
| Dielectric Spectroscopy | 1 | 2019 | 30 | 0.040 |
Why?
|
| Heart Failure | 2 | 2014 | 11729 | 0.040 |
Why?
|
| Linear Models | 2 | 2019 | 5859 | 0.040 |
Why?
|
| Palladium | 1 | 2019 | 68 | 0.040 |
Why?
|
| Proportional Hazards Models | 3 | 2019 | 12455 | 0.040 |
Why?
|
| Animals | 4 | 2024 | 166811 | 0.040 |
Why?
|
| History, Ancient | 1 | 2019 | 211 | 0.040 |
Why?
|
| Methylene Blue | 1 | 2019 | 151 | 0.040 |
Why?
|
| Pregnancy Trimester, First | 1 | 2023 | 902 | 0.040 |
Why?
|
| Gallbladder Neoplasms | 1 | 2020 | 190 | 0.040 |
Why?
|
| Electrochemical Techniques | 1 | 2019 | 96 | 0.040 |
Why?
|
| Nanotubes, Carbon | 1 | 2019 | 73 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2019 | 278 | 0.040 |
Why?
|
| United States | 2 | 2023 | 71438 | 0.040 |
Why?
|
| Lysophosphatidylcholines | 1 | 2018 | 81 | 0.040 |
Why?
|
| Sample Size | 1 | 2021 | 835 | 0.040 |
Why?
|
| Vegetables | 1 | 2023 | 1196 | 0.040 |
Why?
|
| Chitosan | 1 | 2019 | 130 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2007 | 2266 | 0.040 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2019 | 397 | 0.040 |
Why?
|
| Djibouti | 1 | 2017 |